Based on the key indicators related to Quoin Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Quoin Pharmaceuticals Ltd may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Quoin Pharmaceuticals' Net Tangible Assets are fairly stable compared to the past year. Accounts Payable is likely to rise to about 951 M in 2025, whereas Property Plant And Equipment Net is likely to drop slightly above 1.3 M in 2025. Key indicators impacting Quoin Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Quoin Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Quoin Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Quoin Pharmaceuticals.
Please note, the imprecision that can be found in Quoin Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Quoin Pharmaceuticals Ltd. Check Quoin Pharmaceuticals' Beneish M Score to see the likelihood of Quoin Pharmaceuticals' management manipulating its earnings.
Quoin Pharmaceuticals Stock Summary
Quoin Pharmaceuticals competes with Revelation Biosciences, Virax Biolabs, Allarity Therapeutics, Biodexa Pharmaceticals, and Unicycive Therapeutics. Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Quoin Pharmaceuticals, Ltd. was incorporated in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Quoin Pharmaceuticals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Quoin Pharmaceuticals. It measures of how well Quoin is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Quoin Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Quoin had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Quoin Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Quoin Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Quoin Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Quoin Pharmaceuticals competition to find correlations between indicators driving Quoin Pharmaceuticals's intrinsic value. More Info.
Quoin Pharmaceuticals Ltd is rated fourth in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Quoin Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Quoin Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Quoin Pharmaceuticals Systematic Risk
Quoin Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Quoin Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Quoin Pharmaceuticals correlated with the market. If Beta is less than 0 Quoin Pharmaceuticals generally moves in the opposite direction as compared to the market. If Quoin Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Quoin Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Quoin Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Quoin Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Quoin Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Quoin Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Quoin Pharmaceuticals growth as a starting point in their analysis.
Quoin Pharmaceuticals March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Quoin Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Quoin Pharmaceuticals Ltd. We use our internally-developed statistical techniques to arrive at the intrinsic value of Quoin Pharmaceuticals Ltd based on widely used predictive technical indicators. In general, we focus on analyzing Quoin Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Quoin Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.